E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC
E Fund Management Co. Ltd. has acquired 45,895 shares of Celcuity, Inc. (NASDAQ:CELC), valued at approximately $4.8 million, representing a 0.09% stake in the company. Institutional investors collectively own 63.33% of Celcuity, with several firms adjusting their positions. Despite a recent earnings miss and a stock price below its 52-week high, analysts maintain a "Moderate Buy" consensus rating with an average price target of $154.55.
Celcuity (NASDAQ: CELC) insider updates stock holdings
Celcuity Inc. Chief Science Officer, Lance G. Laing, reported insider transactions via a Form 4 filing, indicating a net purchase of 20,000 shares. These transactions involved the grant of 20,000 common stock shares and 10,000 performance stock units. The common stock vests over four years, while performance units vest upon achieving specific share price thresholds.
Celcuity keeps cool amid questions about Revtorpyk launch timing
Celcuity is addressing investor concerns regarding the slower-than-expected launch of its breast cancer drug, Revtorpyk, which led to a significant stock drop. The delay is primarily due to awaiting FDA approval for a second manufacturing facility. Despite this, the company remains confident in the drug's potential, anticipating annual sales exceeding $6 billion, and expects shipments to begin by the end of the third quarter.
Citizens reiterates Celcuity stock rating ahead of drug launch
Citizens has reiterated its Market Outperform rating and $177.00 price target for Celcuity Inc (NASDAQ:CELC) following the company's second-quarter 2026 financial results and updates on its drug REVTORPYK. The drug is anticipated to launch in late third-quarter 2026, with regulatory aspects expected to be complete prior to launch. Despite a wider-than-expected loss in Q2 2026 due to pre-launch spending, Celcuity maintains strong clinical data and sufficient cash reserves through 2029, with Wall Street analysts remaining bullish on the stock.
Celcuity's (CELC) "Market Outperform" Rating Reiterated at Citizens Jmp
Citizens Jmp has reiterated its "Market Outperform" rating for Celcuity (NASDAQ:CELC), setting a price target of $177, which suggests a 92% potential upside. Despite missing quarterly adjusted earnings estimates, analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $153.64, as institutional investors hold a significant stake in the company. Celcuity, a clinical-stage biotechnology company, specializes in precision oncology diagnostics to optimize cancer treatment selection.
Guggenheim raises Celcuity stock price target on drug pricing data
Guggenheim raised its price target on Celcuity Inc (NASDAQ:CELC) to $175 from $165, maintaining a Buy rating, citing the higher-than-expected disclosed price of Revtorpyk. Celcuity plans to begin commercial shipments of Revtorpyk in late Q3 and submit a supplemental new drug application for PIK3CAm in Q3 2026. Despite a wider-than-expected loss in Q2 2026, the company holds a strong cash balance and positive analyst outlooks, although some price targets have been adjusted.
H.C. Wainwright reiterates Celcuity stock rating on pricing update
H.C. Wainwright has reiterated its Buy rating and $155 price target for Celcuity Inc (NASDAQ:CELC) following the company's Q2 results and corporate update, despite the stock being considered overvalued by InvestingPro data. Analysts maintain a Strong Buy consensus, with price targets ranging from $140 to $178. Celcuity has set a wholesale acquisition cost of $10,000 per vial for its REVTORPYK regimen, which has been named a preferred Category 1 option by the National Comprehensive Cancer Network, and commercial shipments are on track for late Q3 2026.
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Celcuity Inc. (NASDAQ:CELC) following a significant drop in its stock price. The investigation stems from Celcuity's announcement of FDA approval for its breast cancer therapy, Revtorpyk, with an anticipated commercial launch in late Q3 2026, which analysts deemed a delayed timeline. Investors who purchased Celcuity securities are encouraged to contact the firm to assist in the investigation.
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status
Celcuity Inc. (CELC) reported a wider Q2 net loss of US$78.86 million, but its investment outlook has been reshaped by the FDA approval and NCCN Category 1 status for its drug Revtopik in HR-positive, HER2-negative advanced breast cancer. This approval shifts the focus from binary trial events to commercialization execution, with potential initial revenue generation in late Q3 2026. Despite accelerating cash burn and reliance on financing, the market's previous cautious revenue forecasts for Celcuity may need to be revised upwards due to Revtopik's strong efficacy data and rapid guideline endorsement.
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status
Celcuity Inc. (CELC) reported a wider Q2 net loss of US$78.86 million but secured FDA approval and NCCN Category 1 status for Revtopik, its breast cancer drug. This development significantly alters the company's investment narrative, shifting focus from gedatolisib's potential to Revtopik's commercialization and its ability to offset increasing losses. The rapid guideline endorsement is expected to lead to initial revenue generation by late Q3 2026, though investors are cautioned to consider the company's accelerating cash burn and reliance on financing.
Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Celcuity (NASDAQ:CELC) from a "sell" to a "strong sell," despite a "Moderate Buy" consensus from other analysts with an average price target of $153.64. The company's shares opened at $92, below its 52-week high, and reported a larger-than-expected quarterly loss of $1.44 per share, missing consensus estimates. Institutional investors currently hold 63.33% of the stock.
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS
Celcuity (NASDAQ:CELC) recently reported its quarterly earnings, missing analyst estimates with a loss of $1.44 per share against a consensus of $1.16, and revenue of $0.09 million, significantly below the $4.42 million forecast. Despite the financial miss, the company highlighted the FDA approval of REVTORPYK and its strong performance in clinical trials for advanced breast cancer, with commercial shipments expected to begin in late Q3 2026. Celcuity's net loss widened to $78.9 million due to launch expenses, but it ended June with $754 million in cash, providing funding through 2029.
Celcuity remains a Buy as FDA approval and strong trial data boost confidence in its cancer drug launch.
Celcuity Inc. has received a "Buy" rating following the FDA approval of its cancer drug REVTORPYK/gedatolisib and its quick inclusion in NCCN Category 1 guidelines, which is expected to aid adoption. Despite high upfront commercial investments and a significant valuation, the company's strong cash position and positive clinical trial results suggest a promising market launch and potential for label expansion and earnings growth.
Stifel cuts Celcuity stock price target on refined market model
Stifel lowered its price target for Celcuity Inc. (NASDAQ:CELC) to $150 from $175, while maintaining a Buy rating, citing refined market model inputs for Revtorpyk and higher future administrative expenses. Despite the stock's strong performance, InvestingPro analysis suggests it might be overvalued, and analysts do not anticipate profitability this year. The company is preparing for the commercial launch of Revtorpyk in late Q3 2026, supported by strong liquidity and an ongoing Expanded Access Program.
Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside
Analysts have adjusted Celcuity Inc.'s average 12-month price target from $163.55 to $160.64, with individual forecasts ranging from $140 to $178 per share. This new target suggests an 85% potential upside from the Aug. 13 closing price. The consensus rating for Celcuity Inc. remains a "Buy" among 12 analysts.
Needham cuts Celcuity stock price target on updated revenue model
Needham has reduced its price target for Celcuity Inc (NASDAQ:CELC) shares to $140 from $157, while maintaining a Buy rating. This adjustment follows the approval and upcoming launch of Revtorpyk, with Needham updating its revenue models to an incidence-based approach and incorporating new pricing and treatment-duration information. Despite the stock trading below its 52-week high, it has seen significant returns, though InvestingPro analysis suggests it is overvalued and the company is not expected to be profitable this year.
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
Celcuity Inc. announced its Q2 2026 financial results, highlighted by the FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- PIK3CA Wild-Type breast cancer and its inclusion in NCCN guidelines. The company plans a commercial launch for REVTORPYK in late Q3 2026 and intends to submit an sNDA for the PIK3CA mutant cohort of the VIKTORIA-1 trial. Financially, Celcuity reported a net loss of $78.9 million for the quarter, with cash and equivalents totaling $754.0 million, projected to fund operations until at least 2029.
Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity
Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value CELC at $161.09, which is considerably higher than its current trading price of $86.60, suggesting it may be undervalued despite being a pre-revenue company.
CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch
Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting the stage for a commercial launch in late Q3 2026. This summary is AI-generated and requires verification with the original source.
CELCUITY ($CELC) Releases Q2 2026 Earnings
CELCUITY ($CELC) reported Q2 2026 earnings, missing analyst estimates with -$1.44 per share, compared to an expected -$1.19, and revenue of $0, matching estimates. Insider trading activity for CELC in the last six months shows nine sales and no purchases. Institutional investors have had mixed activity, with 144 adding shares and 140 decreasing positions, while analysts have set a median price target of $160.0 for the stock.
Celcuity beats second quarter loss estimates
Celcuity Inc. reported an adjusted loss of $1.07 per share for the second quarter of 2026, surpassing analyst estimates. The company's shares rose 1% after the announcement, driven by the recent FDA approval of its breast cancer treatment, REVTORPYK. Celcuity expects to begin shipments of REVTORPYK late in the third quarter of 2026 and plans to submit a supplemental New Drug Application for a different patient population.
Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12
Celcuity Inc. (CELC) reported a Q2 adjusted loss of $1.07 per share, which was better than the FactSet estimate of $-1.12 per share. The article, published on August 13, 2026, also noted that Celcuity's Q2 adjusted loss widened. This news follows several recent developments for the company, including FDA approval for its REVTORPYK drug.
Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity
Celcuity (CELC) received FDA approval for REVTORPYK and inclusion in National Comprehensive Cancer Network guidelines, yet its share price has fallen significantly in recent months, trading at a discount to analyst targets. Analysts forecast substantial revenue by 2029 for the pre-revenue company, suggesting a strong upside despite current market skepticism. Investors are now evaluating whether the recent pullback represents a buying opportunity or signals potential risks related to future data and regulatory processes.
Celcuity, Inc. (NASDAQ:CELC) Receives Average Recommendation of "Moderate Buy" from Brokerages
Celcuity, Inc. (NASDAQ:CELC) has received an average "Moderate Buy" rating from eleven brokerages, with ten assigning a buy rating and one a sell rating. The average 12-month price target is $155.18, significantly higher than its current price of $92.08. The company recently reported quarterly EPS of -$0.97, surpassing analyst estimates, and institutional investors hold 63.33% of its stock.
Bank of America Corp DE Sells 262,789 Shares of Celcuity, Inc. $CELC
Bank of America Corp DE reduced its stake in Celcuity, Inc. (NASDAQ:CELC) by 26.9% during the first quarter, selling 262,789 shares but still holding 714,329 shares valued at $81.5 million. Despite the share reduction, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $155.18, following the company's better-than-expected quarterly earnings report. Celcuity, a clinical-stage biotechnology company focused on precision oncology diagnostics, opened at $92.79, below its 200-day moving average.
California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC
The California State Teachers Retirement System has significantly increased its stake in Celcuity, Inc. (NASDAQ:CELC) by 91.2%, purchasing an additional 12,201 shares, bringing its total holdings to 25,580 shares valued at $2.92 million. Despite this institutional interest, the company's shares opened at $92.79, below their 52-week high, following a reported quarterly loss of $0.97 per share, which nonetheless beat analyst expectations. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $155.18, reflecting optimism about the clinical-stage biotechnology firm specializing in precision oncology diagnostics.
Understanding the Setup: (CELC) and Scalable Risk
An analysis of Celcuity Inc. (NASDAQ: CELC) indicates strong near-term sentiment but elevated downside risk. AI-generated trading strategies are provided for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The article highlights the importance of institutional trading strategies for optimizing position sizing and minimizing drawdown risk.
Celcuity Inc (CELC) Stock News Today
This page provides current news and analysis for Celcuity Inc (CELC), including its stock performance and market data. It lists recent stock movements for other pharmaceutical companies like Bristol-Myers Squibb Co (BMY), Novo Nordisk A/S (NVO), and Merck & Co Inc (MRK). The content focuses on financial updates and key developments relevant to investors.
Celcuity faces investigation after FDA approval delays cause stock to drop 17.6%.
Pomerantz LLP is investigating Celcuity Inc. for potential securities fraud. This follows a 17.6% stock drop on July 15, 2026, after Celcuity announced delays in the commercial launch of its FDA-approved breast cancer therapy, Revtorpyk. The investigation aims to determine if unlawful business practices occurred, and affected investors are encouraged to contact the law firm.
Celcuity Inc. (CELC) Stock Price, News, Quote & History
This page provides a comprehensive overview of Celcuity Inc. (CELC) stock, including its real-time price, historical data, and financial performance. It highlights the company's focus on developing targeted therapies for solid tumors and its lead drug candidate, Gedatolisib. The page also includes analyst insights, earnings trends, and valuation measures for investors.
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Inc. announced it will release its second quarter 2026 financial results after the market closes on Thursday, August 13, 2026. Management will host a webcast/teleconference on the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate update. The company is a commercial-stage biotechnology firm focused on developing and commercializing targeted therapies for multiple solid tumor indications.
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Inc. (Nasdaq: CELC), a biotechnology company, announced it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. Management will host a webcast/teleconference on the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate update. Details for participation in the teleconference and webcast were provided.
Celcuity Inc. (NASDAQ:CELC): When Will It Breakeven?
This article analyzes Celcuity Inc.'s path to profitability, focusing on analyst expectations for its breakeven point. It discusses the company's current losses and projected future performance, highlighting key financial metrics and growth forecasts. The article also provides insight into the factors influencing Celcuity's profitability timeline.
Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc.
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Celcuity Inc. (NASDAQ:CELC) following a significant drop in its stock price. The investigation stems from Celcuity's announcement of a delayed commercial launch for its breast cancer therapy, Revtorpyk, which fell short of analyst expectations. Investors who suffered losses are encouraged to contact the firm.
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP is investigating Celcuity Inc. (NASDAQ: CELC) on behalf of investors for potential securities law violations. This investigation follows a significant drop in Celcuity's stock price after the company announced U.S. FDA approval for its breast cancer therapy, Revtorpyk, but with a delayed commercial launch timeline (late Q3 2026) that disappointed analysts. Investors who purchased Celcuity securities and wish to learn more about the investigation are encouraged to contact the law firm.
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP is investigating potential securities law violations by Celcuity Inc. after its stock price fell following an announcement of a delayed commercial launch for its breast cancer therapy, Revtorpyk. The delay to late Q3 2026, which was later than analyst expectations, caused a significant drop in Celcuity's stock. Investors who purchased Celcuity securities are encouraged to contact the law firm to discuss their rights.
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP is investigating potential securities law violations by Celcuity Inc. (NASDAQ: CELC) and its senior management. This investigation follows a July 13, 2026, announcement by Celcuity regarding FDA approval for its breast cancer therapy, Revocirib, which included a delayed commercial launch timeline compared to analyst expectations, causing a significant stock price drop. Investors who purchased Celcuity securities and have information or wish to discuss their rights are encouraged to contact the law firm.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Celcuity Inc. (CELC) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Celcuity Inc. (NASDAQ:CELC) following a significant drop in its stock price. This decline occurred after Celcuity announced U.S. FDA approval for its breast cancer therapy Revtorpyk, but with a commercial launch timeline in late Q3 2026, which was later than analyst expectations. Shareholders who purchased Celcuity securities are encouraged to connect with the firm to assist in the investigation.
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Celcuity Inc. (NASDAQ: CELC) on behalf of investors, following a significant drop in share price. The investigation concerns potential violations of securities laws, specifically focusing on whether Celcuity made false or misleading statements regarding the delayed commercial launch of its breast cancer treatment, Revtorpyk (gedatolisib), after receiving FDA approval. Shareholders who suffered losses are encouraged to contact SBS to discuss their rights.
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations by Celcuity Inc. (NASDAQ: CELC) on behalf of investors. The investigation stems from Celcuity's announcement of FDA approval for its breast cancer treatment, Revtorpyk, with a commercial launch slated for late Q3 2026, which was later than analysts expected and led to a 17.6% drop in stock price. SBS is encouraging affected shareholders to join the investigation to discuss their rights.
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) is investigating potential securities law violations by Celcuity Inc. (NASDAQ: CELC) on behalf of its investors. This probe follows a 17.6% drop in Celcuity's share price after the company announced FDA approval for its breast cancer treatment, Revtorpyk, with a commercial launch timeline that was later than analyst expectations. SBS encourages affected shareholders to join the investigation.
CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating Celcuity Inc. (NASDAQ: CELC) for potential violations of federal securities laws after the company announced a delayed commercial launch for its breast cancer therapy, Revtorpyk. This delay, pushing the launch to late Q3 2026, was unexpected by analysts and led to a more than 17% drop in Celcuity's stock price. The law firm is encouraging investors who experienced financial losses to contact them to discuss their legal rights.
Is REVTORPYK’s First‑in‑Class FDA Approval Reframing the Investment Case For Celcuity (CELC)?
Celcuity recently received FDA approval and NCCN Category 1 preferred guideline status for its drug REVTORPYK (gedatolisib), specifically for HR+/HER2- breast cancer. This approval is significant as REVTORPYK is the only FDA-approved therapy targeting all class I PI3K isoforms and both mTORC1 and mTORC2 complexes. The approval, coupled with a recent $500 million convertible note offering, shifts Celcuity's investment narrative from a pre-commercial "cash burning" entity to one focused on commercial launch and product uptake, though execution risk remains if adoption lags expectations.
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Celcuity Inc. announced that its newly FDA-approved drug, REVTORPYK (gedatolisib), has been included as a preferred Category 1 regimen in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines. This inclusion is for the second-line treatment of HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation. The drug was approved by the FDA on July 14, 2026, based on positive results from the Phase 3 VIKTORIA-1 trial, which showed significant improvement in progression-free survival and objective response rates.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celcuity Inc. (CELC) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Celcuity Inc. (NASDAQ:CELC) on behalf of investors. This follows a significant drop in Celcuity's stock price after the company announced FDA approval for its breast cancer therapy, Revtorpyk, but with a delayed commercial launch timeline compared to analyst expectations. The law firm is encouraging shareholders to come forward and assist in the investigation.
Celcuity Inc. (CELC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims on behalf of Celcuity Inc. (NASDAQ:CELC) purchasers. This follows a significant drop in Celcuity's stock price after the company announced FDA approval for its breast cancer therapy, Revtorpyk, but with a delayed commercial launch timeline for late Q3 2026, which disappointed analysts. The law firm is encouraging affected investors to contact them to assist with the investigation.
Celcuity's stock drops 17% after delayed launch of FDA-approved breast cancer drug Revtorpyk.
Celcuity's stock fell 17% after the company announced a delay in the commercial launch of its FDA-approved breast cancer drug, Revtorpyk, now expected in late Q3 2026. This delay has prompted a law firm, Kessler Topaz Meltzer & Check LLP, to investigate potential securities law violations, allowing affected investors to pursue legal claims.
NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating Celcuity Inc. (NASDAQ: CELC) for potential violations of federal securities laws after the company announced a delayed commercial launch for its breast cancer therapy, Revtorpyk. This delay, which pushed the launch to late Q3 2026, was contrary to analyst expectations and resulted in a stock price drop of over 17%. Investors who experienced losses are encouraged to contact the firm regarding their legal rights.
Celcuity Inc (CELC) Institutional Confidence
The article analyzes Celcuity Inc's (CELC) institutional confidence, noting its high score of 10.00, which ranks it 1st out of 385 in the Biotechnology & Medical Research industry. Institutional shareholding is 97.67%, with a 12.26% quarter-over-quarter increase. Steven Cohen is the largest institutional shareholder.
NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP (KTMC) is investigating potential federal securities law violations by Celcuity Inc. (NASDAQ: CELC) after the company announced an unexpected delay in the commercial launch of its breast cancer therapy, Revtorpyk. This delayed timeline, relative to analyst expectations, caused Celcuity's stock price to fall over 17%. KTMC is urging investors who suffered losses to contact the firm to discuss their legal rights.
